BJT-778-303

• Research type

  Research Study

• Full title

  A Phase 2b/3, Open-Label, Multicenter Trial Evaluating the Efficacy and Safety of Switching to Brelovitug for the Treatment of Chronic Hepatitis Delta Infection in Participants Receiving Bulevirtide (AZURE-3)

• IRAS ID

  1012692

• Contact name

  Linda Woo

• Contact email

  lwoo@bluejaytx.com

• Sponsor organisation

  Bluejay Therapeutics, Inc.

• Research summary

  This is a randomized, open-label study which means the study doctors and participants will know what treatment is being given. Participants who have been taking bulevirtide for 6 months or more with HDV levels that are greater than 100 IU/mL may enroll in this study.
  Participants will stop bulevirtide treatment and be randomly (purely by chance) assigned to one of two groups. The second group will continue bulevirtide for 24 weeks then switch to brelovitug 300 mg once a week for 72 weeks.

• REC name

  London - London Bridge Research Ethics Committee

• REC reference

  25/LO/0758

• Date of REC Opinion

  24 Nov 2025

• REC opinion

  Further Information Favourable Opinion